WAVEMAN · COMPANY

VCYT · Veracyte, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

VCYT

Name: VERACYTE, INC. (VCYT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

VERACYTE, INC.

HEALTHCARE SERVICES · SERVICES-MEDICAL LABORATORIES · CIK 0001384101

CONGRESS · 1FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$10.2M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

211

13F, latest reported quarter

REVENUE GROWTH

+16.0%

XBRL, annual

NET MARGIN

12.8%

CONVERSIONS · 180D

codes C/M, not in net · $5.6M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$10.2M over 180 days

-$277.3K over 90 days

below 69% of Healthcare Services

CONGRESS

1 member bought in the last year

the lowest in Healthcare Services

FUNDS

211 funds added or opened last quarter

more than 79% of Healthcare Services

REVENUE

+16.0% year over year

more than 60% of Healthcare Services

MARGIN

12.8% net margin

more than 94% of Healthcare Services

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$10.2M across 8 people in 180 days.

211 funds added or opened positions in the latest 13F quarter, of 372 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +49.1%

+49.1%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $10.2M sold by insiders over 180 days, 211 funds added last quarter, 1 Congress member(s) bought in 12 months, $352.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

NTRA CSTL PGNY HIMS WGS PRVA TDOC AVAH GH ADUS SERA BDSX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, VERACYTE, INC. insiders sold a net $10.2M of stock across 172 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Febbo Phillip G.

Chief Scientific & Med Officer

SELL

2026-09-04

10,405.0

$446.3K

Febbo Phillip G.

Chief Scientific & Med Officer

SELL

2026-09-04

2,705.0

$118.1K

Chambers Rebecca

Chief Financial Officer

SELL

2026-09-04

2,477.0

$106.0K

Chambers Rebecca

Chief Financial Officer

SELL

2026-09-04

1,175.0

$51.4K

McGuire Annie

EVP, General Counsel

SELL

2026-09-04

2,154.0

$92.2K

172 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 167 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

13,486,437.0 sh

$792.1M

FMR LLC

7,702,746.0 sh

$452.4M

Artisan Partners Limited Partnership

5,538,404.0 sh

$325.3M

VANGUARD PORTFOLIO MANAGEMENT LLC

4,716,191.0 sh

$277.0M

STATE STREET CORP

4,698,128.0 sh

$276.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

MUNA BHANJI

FILED 2026-09-01

$161.0K

KARIN EASTHAM

FILED 2026-06-18

$191.3K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

First Trust NYSE Arca Biotechnology Index Fund

$61.8M POSITION · AS OF 2026-03-31

2.7%

ARK Genomic Revolution ETF

$32.9M POSITION · AS OF 2026-04-30

2.7%

Invesco Biotechnology & Genome ETF

$6.5M POSITION · AS OF 2026-04-30

2.6%

Global X Genomics & Biotechnology ETF

$1.3M POSITION · AS OF 2026-02-28

2.4%

ALGER WEATHERBIE SPECIALIZED GROWTH FUND

$5.9M POSITION · AS OF 2026-04-30

2.1%

Oberweis Global Opportunities Fund

$1.1M POSITION · AS OF 2026-03-31

1.9%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Bonnie Anderson

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$7.4M

$9.6M

$2.8M

-14%

+25%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$517.1M	$445.8M	$361.1M	$296.5M
GROSS PROFIT	$362.5M	$298.1M	$229.7M	$175.7M
OPERATING INCOME	$57.8M	$16.1M	$-85.8M	$-41.1M
NET INCOME	$66.4M	$24.1M	$-74.4M	$-36.6M
EPS (DILUTED)	0.82	0.31	-1.02	-0.51
OPERATING CASH FLOW	$136.3M	$75.1M	$44.2M	$7.5M
CASH	$362.6M	$239.1M	$216.5M	$154.2M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE